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Objective: Routinely collected health data may be valuable sources for conducting research. 
This study aimed to evaluate the validity of algorithms detecting hypopituitary patients in the 
Danish National Patient Registry (DNPR) using medical records as reference standard.
Study design and setting: Patients with International Classification of Diseases (10th edition 
[ICD-10]) diagnoses of hypopituitarism, or other diagnoses of pituitary disorders assumed to be 
associated with an increased risk of hypopituitarism, recorded in the DNPR during 2000–2012 
were identified. Medical records were reviewed to confirm or disprove hypopituitarism.
Results: Hypopituitarism was confirmed in 911 patients. In a candidate population of 1,661, 
this yielded an overall positive predictive value (PPV) of 54.8% (95% confidence interval [CI]: 
52.4–57.3). Using algorithms searching for patients recorded at least one, three or five times with 
a diagnosis of hypopituitarism (E23.0x) and/or at least once with a diagnosis of postprocedural 
hypopituitarism (E89.3x), PPVs gradually increased from 73.3% (95% CI: 70.6–75.8) to 83.3% 
(95% CI: 80.7–85.7). Completeness for the same algorithms, however, decreased from 90.8% 
(95% CI: 88.7–92.6) to 82.9% (95% CI: 80.3–85.3) respectively. Including data of hormone 
replacement in the same algorithms PPVs increased from 73.2% (95% CI: 70.6–75.7) to 82.6% 
(95% CI: 80.1–84.9) and completeness decreased from 94.3% (95% CI: 92.6–95.7) to 89.7% 
(95% CI: 87.5–91.6) with increasing records of E23.0x.
Conclusion: The DNPR is a valuable data source to identify hypopituitary patients using a 
search criteria of at least five records of E23.0x and/or at least one record of E89.3x. Complete-
ness is increased when including hormone replacement data in the algorithm. The consequences 
of misclassification must, however, always be considered.
Keywords: ICD-10 algorithms, registry health data, hypopituitarism
Introduction
Hypopituitarism is defined as deficiency of one or more hormones from the anterior or 
posterior pituitary gland. Common causes are pituitary adenomas and their treatment, 
radiotherapy of intracranial tumors and surgery near the pituitary gland. The clinical 
presentation of hypopituitarism is heterogeneous and varies according to type and extent 
of hormonal loss. However, it is associated with increased morbidity1 and mortality.2,3
Routinely collected health data are valuable for many different purposes including 
administrative health system planning and epidemiologic surveillance studies determining 
disease outcome over time.4 Denmark is unique in having numerous continuously updated 
population-based health registries with a high level of completeness, where the individual-
level data recording and unique personal identifiers provide an invaluable opportunity to 
link registries and follow patients over time.4,5 Further, it allows identification of specific 
Correspondence: Agnethe Berglund
Department of Endocrinology and 
Internal Medicine, Aarhus University 
Hospital, Nørrebrogade 44, DK-8000 
Aarhus, Denmark 
Tel +45 7845 0000 
Email agnetheberglund@dadlnet.dk
Journal name: Clinical Epidemiology
Article Designation: ORIGINAL RESEARCH
Year: 2017
Volume: 9
Running head verso: Berglund et al
Running head recto: Identification of hypopituitary patients in routinely recorded health data
DOI: http://dx.doi.org/10.2147/CLEP.S124340
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
12
-A
pr
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2017:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
76
Berglund et al
cohorts rapidly. Nevertheless, using routinely recorded health 
data, the risk of misclassification should always be considered. 
Thus, studies evaluating codes and algorithms (combinations 
of routinely collected health data) used to identify patients 
with a specific condition are a prerequisite for using routinely 
collected data in epidemiologic research.6,7
To our knowledge, no study has reported the validity of the 
International Classification of Diseases (10th edition [ICD-10]) 
diagnoses of hypopituitarism in administrative health regis-
tries. We conducted a study aiming to estimate the positive 
predictive value (PPV) as well as completeness of ICD-10 
diagnoses of hypopituitarism in the Danish National Patient 
Registry (DNPR). Based on experience from a previous Dan-
ish registry study on growth hormone deficiency (GHD),8 we 
expected relatively low PPVs of the ICD-10 diagnoses of hypo-
pituitarism. Previous studies from the DNPR evaluating ICD 
diagnoses of acromegaly9 and craniopharyngiomas10 reported 
low PPVs, which however were improved using algorithms 
for the searches. An algorithm-based search for patients with 
nonfunctioning pituitary adenomas in The Swedish National 
Patient Registry showed a PPV as high as 91%.11 Therefore, we 
also aimed to develop and evaluate algorithms for identification 
of hypopituitary patients in the DNPR using combinations of 
ICD-10 diagnoses and data of hormone replacement therapy.
Methods
Setting
Denmark is divided into five administrative regions. The 
Central Denmark Region has ~1.3 million inhabitants and 
accordingly 23% of the total Danish population. Inhabitants 
are primarily referred to hospitals in their home region, thus 
it can be assumed that the source population for this study 
included all inhabitants in the Central Denmark Region.
The health care system in Denmark is a public tax-funded 
system ensuring all citizens equal access to health care. Since 
1968, all persons residing in Denmark have been assigned 
a unique 10-digit civil registration number from which date 
and year of birth, as well as gender, can be identified. The 
civil registration number enables accurate matching of data 
from different data sources.
The DNPR
The DNPR contains data on all nonpsychiatric admissions 
to hospitals since 1977, and likewise data on all outpatient 
contacts since 1996. Among included data are dates of 
admissions and discharges, discharge diagnoses, informa-
tion of the institutional origin of the discharge diagnoses 
as well as surgery and treatment procedures. Diagnoses are 
classified according to the International Classification of 
Diseases (eighth edition until 1993 [ICD-8], and thereafter 
ICD-10).
Hormone replacement
Hypopituitary patients in Denmark are offered free of charge 
hormone replacement administered by hospital pharmacies 
or by endocrine or pediatric departments. We searched the 
hospital pharmacy database at Aarhus University Hospital, 
which covers all administrations of hormones from Aarhus 
University Hospital during 1997–2014 and all hospitals in 
Central Denmark Region from 2014 and onward, on follow-
ing Anatomical Therapeutic Chemical Classification System 
codes: H01AC01 (somatropin), H02AB09 (hydrocortisone), 
H03AA01 (levothyroxine sodium), H03AA02 (liothyronine 
sodium), H01BA (vasopressin analogous) and G03B, G03C 
and G03F (sex hormones).
Data of hormone replacement administered by periph-
eral hospitals in Central Denmark Region before 2014 were 
retrieved from endocrine and pediatric departments. Com-
bined, data were retrieved for 664 patients in the candidate 
cohort, hereof 657 patients from the dataset retrieved from 
the hospital pharmacy at Aarhus University Hospital.
Medical record evaluation
The candidate population was identified in January 2013 
searching the DNPR for all individuals recorded at least once, 
at any age, from January 1, 2000, to December 31, 2012, with 
a primary or secondary ICD-10 diagnosis of hypopituitarism 
or a diagnosis presumed to be associated with an increased 
risk of being hypopituitary (Table 1). Based on this dataset, 
the medical records were identified and reviewed.
Criteria for the diagnosis of hypopituitarism are shown in 
Table 2. The primary review of medical records was done elec-
tronically, and when insufficient to make a definite confirmation 
or disproval of hypopituitarism, paper records were identified 
at one or more departments. If a diagnosis of hypopituitarism 
could not be confirmed after thorough record review, the status 
of the patient was considered nonhypopituitary. When in doubt, 
a senior specialist in endocrinology and hypopituitarism was 
consulted, and status was decided by consensus. In the follow-
ing, those patients with verified hypopituitarism according to 
this method are named confirmed patients. Besides the status of 
hypopituitarism, the cause of hypopituitarism was assessed and 
registered during the medical record review as well. The medi-
cal record review took place from October 2014 to April 2016.
Data analysis
Validation metrics included PPVs and completeness using 
the medical record review as reference standard.
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The PPV was defined as the proportion of confirmed 
patients among all patients in the DNPR with records of 
candidate ICD-10 diagnoses. Analyses were stratified by 
gender, type of diagnosis (primary or secondary), age at 
onset (childhood onset [CO] or adulthood onset [AO]) of 
hypopituitarism, use of hormone replacement, and by year 
of first diagnosis (before or after 2000). CO and AO hypo-
pituitarism were defined as first year of registration with 
a candidate ICD-8 code (Table 3) or a candidate ICD-10 
code before or after an age cutoff of 18 years. Year of first 
diagnosis was defined as the first year of registration with a 
candidate ICD-8 or ICD-10 code or first year of registration 
with E23.0x or E89.3x.
Completeness of ICD-10 diagnoses and algorithms were 
computed as the proportion of identified patients in the DNPR 
out of all confirmed hypopituitary patients.
Two main types of algorithms were evaluated: 1) algo-
rithms based on ICD-10 diagnoses of hypopituitarism only 
and 2) algorithms based on ICD-10 diagnoses of hypopitu-
itarism combined with data of hormone replacement. Both 
types of algorithms were evaluated for at least one, three or 
five records of E23.0x (hypopituitarism, and/or at least one 
record of E89.3x (post-procedural hypopituitarism). E23.0x 
and E89.3x were selected for the algorithms, as they displayed 
the most favorable compromise between PPV and complete-
ness during initial explorative analyses.
All evaluations were made using a dataset retrieved from the 
DNPR May 2016. Prevalence was estimated as the number of 
confirmed hypopituitary patients divided by the average number 
of inhabitants in Central Denmark Region during 2000–2012 
(http://www.noegletal.dk). Confidence intervals (CIs) were esti-
mated as 95% CIs. All analyses were made in StataCorp 13.1.
Ethics
The study was approved by the Danish Data Protection 
Agency (journal number: 2012-41-0149) and by the  Danish 
Table 1 ICD-10 diagnoses used for identification of the candidate 
population
ICD-10 code Diagnosis
C75.1 Malignant neoplasm of pituitary gland
C75.2 Malignant neoplasm of craniopharyngeal duct
D35.2xa Benign neoplasm of pituitary gland
D35.3 Benign neoplasm of craniopharyngeal duct
D44.3 Neoplasm of pituitary gland, unspecified
D44.4 Neoplasm of craniopharyngeal duct, unspecified
E23.0xa Hypopituitarism
E23.1 Drug-induced hypopituitarism
E23.3 Hypothalamic dysfunction, not elsewhere classified
E23.6xa Other disorders of pituitary gland
E23.7 Disorder of pituitary gland, unspecified
E89.3xa Postprocedural hypopituitarism
Note: aAll underlying diagnoses are included.
Abbreviation: ICD-10, International Classification of Diseases (10th edition).
Table 2 Criteria for the diagnosis of insufficient pituitary axes
GH axis 
1. Two consecutively insufficient GH stimulation tests. Accepted tests 
are ITT, growth hormone-releasing hormone (GHRH) test (alone or 
combined with arginine or pyridostigmine) 
2. One insufficient GH stimulation test AND one or more insufficient 
pituitary axes (biochemically verified)
3. One insufficient GH stimulation test AND one or more other 
pituitary operations 
4. One insufficient GH stimulation test AND pituitary irradiation (if 
this criteria is the only to be fulfilled, the patient is first incident a 
minimum of 5 years interval from first irradiation)
5. One insufficient GH stimulation test and IGF-I <-2SD (relevant age 
and gender) 
6. One insufficient GH stimulation test and a genetic analysis with 
known association with GHD
7. One insufficient GH stimulation test and relevant growth retardation 
8. Clinical interpretation of GHD combined with at least three other 
biochemically verified insufficient pituitary axes
Adrenal axis
1. Synacthen (high or low dose) test or ITT with cortisol response 
<500 nmol/L after 30 minutes
2. Blood samples followed by a clinical interpretation of insufficiency 
Thyroid axis
1. T4 below relevant reference combined with inappropriately low TSH
2. Blood samples followed by a clinical interpretation of insufficiency 
Gonadal axis
1. FSH/LH/testosterone/estradiol below relevant reference 
(In females: dependent on pre- or postmenopausal status)
2. Blood samples followed by a clinical interpretation of insufficiency 
3. Amenorrhea followed by a clinical interpretation of insufficiency
4. Insufficient secondary sexual development 
ADH axis
1. Insufficient response to water deprivation test 
2. Clinical interpretation of insufficiency followed by successful medical 
treatment
Abbreviations: GH, growth hormone; ITT, insulin tolerance test; IGF-1, insulin-
like growth factor 1; SD, standard deviation; GHD, growth hormone deficiency; T4, 
thyroxin; TSH, thyroid stimulation hormone; FSH, follicle-stimulating hormone; LH, 
luteinizing hormone; ADH, antidiuretic hormone.
Table 3 ICD-8 diagnoses used to identify incident patients 
before 1993
ICD-8 code Diagnosis
25302 Pituitary adenoma, eosinophilic
25310 Postprocedural hypopituitarism
25313 Pituitary dwarfism, traumatic
25315 Pituitary dwarfism, idiopathic
25318 Hypopituitarism, other specified
25319 Hypopituitarism
25329 Pituitary adenoma, chromophobe
25399 Pituitary disease, other and unspecified
25801 Pituitary adenoma, basophilic
Abbreviation: ICD-8, International Classification of Diseases (eighth edition).
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
12
-A
pr
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2017:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
78
Berglund et al
Health Authorities (journal number: 3-3013-363/1/) as 
required by the Danish law when patient data are involved 
without written informed consent from the patients. Written 
informed consent was deemed not required by these institu-
tions as it would have made this study impossible to accom-
plish as patients included may have died during the process.
Results
Searching the DNPR, 8,694 patients were identified with 
one or more of the candidate ICD-10 diagnoses, and hereof 
had 1,772 patient records from a hospital department in the 
Central Denmark Region. Medical records were accessible 
for 1,737 of these patients and hereof were 911 patients 
confirmed hypopituitary. The pituitary status could not be 
determined in 76 patients leaving a candidate cohort of 
1,661 patients (Figure 1), and a total PPV of 54.8% (95% CI: 
52.4–57.3; Table 4). As the average number of inhabitants in 
Central Denmark Region during 2000–2012 was 1,223,527, 
the average prevalence of hypopituitarism during this period 
was estimated to 74.4 (95% CI: 69.7–79.5) per 100,000.
PPVs stratified by gender, type of diagnosis, hormone 
replacement, age at first candidate diagnosis and time period 
of first candidate diagnosis (before or after 2000) are shown 
in Table 4.
8,694 patients recorded in the Danish
National Patient Registry during 2000–2012
with at least one ICD-10 diagnosis presumed
as associated with increased risk of
hypopituitarism
1,772 patients recorded at least once from a
department in Central Denmark Region
1,737 patients:
medical record evaluation
35 patients: missing
medical record
76 patients: insufficient
information to determine
pituitary status
Pituitary status determined
in 1,661 patients
911 hypopituitary
patients
750 nonhypopituitary
patients
Figure 1 Identification of hypopituitary patients during 2000–2012.
Abbreviation: ICD-10, International Classification of Diseases (10th edition).
Table 4 Positive predictive values stratified by gender, type of 
diagnosis, age at first diagnosis, hormone replacement and year of 
first diagnosis according to the Danish National Patient Registry
 Number of confirmed 
hypopituitary patients 
versus potential 
hypopituitary patients
PPV (95% CI)
Total 911/1,661 54.8 (52.4–57.3)
Gender
Men 531/846 62.8 (59.4–66.0)
Women 380/815 46.6 (43.2–50.1)
Type of diagnosis
Primary or secondary 911/1,661 54.9 (52.4–57.3)
Primary 812/1,389 58.5 (55.8–61.1)
Secondary 481/779 61.8 (58.2–65.1)
Age at diagnosis
<18 years 240/346 69.4 (64.2–74.2)
≥18 years 671/1,315 51.0 (48.3–53.8)
Hormone replacement 593/664 89.3 (86.7–91.5)
Year of first diagnosis
Candidate ICD diagnosis
≤1999 395/466 84.8 (81.2–87.9)
≥2000 516/1,195 43.2 (40.3–46.0)
Diagnosis of E23.0xa or E89.3xa
≤1999 294/301 97.7 (95.3–99.1)
≥2000 533/828 64.4 (61.0–67.6)
Note: aInclusive all underlying diagnoses of E23.0 (hypopituitarism) and E89.3 
(postprocedural hypopituitarism).
Abbreviations: PPV, positive predictive value; CI, confidence interval; ICD, 
International Classification of Diseases.
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had 54.5% (85/156) hormone- or nonhormone producing 
adenomas, including prolactinomas, or idiopathic hypopi-
tuitarism as cause of hypopituitarism, while the remaining 
had a wide spectrum of causes of hypopituitarism. Of con-
firmed patients identified by the same algorithm had 39.2% 
(296/755) idiopathic hypopituitarism or hypopituitarism due 
to hormone- or nonhormone producing adenomas, according 
to the medical record review.
Discussion
In this population-based study, the validity of ICD-10 diagno-
ses of hypopituitarism in the DNPR during 2000–2012 was 
assessed using medical record review as reference standard. 
Alone, neither E23.0x (hypopituitarism) nor E89.3x (post-
procedural hypopituitarism) had sufficient validity for identi-
fication of hypopituitary patients in the DNPR. However, an 
algorithm including at least five records of E23.0x and/or at 
least one record of E89.3x yielded an acceptable compromise 
between PPV and completeness. Completeness was even 
further improved without a concurrent loss in PPV when a 
criterion of hormone replacement was applied to the algorithm.
Table 5 Positive predictive values and estimates of completeness for individual ICD-10 diagnoses of hypopituitarism and related 
pituitary disorders
ICD-10 code Number of confirmed hypopituitary patients 
versus potential hypopituitary patients
PPV (95% CI) Completeness (%)a
E23.0xb 720/982 73.3 (70.4–76.1) 79.0 (76.2–81.6)
E23.1 6/7 85.7 (42.1–99.6) 0.7 (0.2–1.4)
E23.3 11/19 57.9 (33.5–79.7) 1.2 (0.6–2.2)
E23.6xb 93/142 65.5 (57.1–73.3) 10.2 (8.3–12.4)
E23.7 90/173 52.0 (44.3–59.7) 9.9 (8.0–12.0)
E89.3xb 368/414 88.9 (85.5–91.7) 40.4 (37.2–43.7)
C75.1 8/11 72.7 (39.0–94.0) 0.9 (0.4–1.7)
D35.2xb 376/769 48.9 (45.3–52.5) 41.3 (38.1–44.5)
D35.3 87/92 94.6 (87.8–98.2) 9.5 (7.7–11.6)
D44.3 14/51 27.5 (15.9–41.7) 1.5 (0.8–2.6)
D44.4 31/35 88.6 (73.3–96.8) 3.4 (2.3–4.8)
Notes: aCompleteness: proportion of confirmed hypopituitary patients detected during search of the DNPR for the specific ICD-10 code. bAll underlying diagnoses are included.
Abbreviations: ICD-10, International Classification of Diseases (10th edition); PPV, positive predictive value; CI, confidence interval; DNPR, Danish National Patient Registry.
The PPV of E23.0x (hypopituitarism) was 73.3% (95% 
CI: 70.4–76.1) and the PPV of E89.3x (postprocedural hypo-
pituitarism) was 88.9% (95% CI: 85.5–91.7). The PPVs for 
all candidate ICD-10 diagnoses are shown in Table 5. Of all 
confirmed patients (n=911), 90.8% (n=827) had at least one 
record of E23.0x or E89.3x.
The PPVs for algorithms identifying patients recorded 
at least one, three or five times with E23.0x and/or at least 
once with E89.3x ranged from 73.3% (95% CI: 70.6–75.8) 
to 83.3% (95% CI: 80.7–85.7) (Table 6). Including data of 
hormone replacement to the algorithms, PPVs increased 
with an increasing number of records of E23.0x as well. 
Completeness decreased for both types of algorithms, when 
the number of records of E23.0x was increased. However, 
the loss of confirmed patients was lower for the algorithms 
including hormone replacement (Table 6). PPVs were not 
improved for any of the algorithms when stratifying on CO 
and AO patients, respectively.
One-hundred and fifty-six confirmed patients were not 
identified by the algorithm that included at least five records 
of E23.0x and/or at least one record of E89.3x, and of those 
Table 6 Positive predictive values and completeness for algorithms combining ICD-10 diagnoses and hormone replacement therapy
ICD-10 algorithms Number of confirmed hypopituitary patients 
versus potential hypopituitary patients
PPV (95% CI) Completenessa (%)
1. Algorithms for at least one, three or five records of E23.0x and/or at least one record of E89.3x
E23.0x ≥ 1 and/or E89.3x ≥ 1 827/1,129 73.3 (70.6–75.8) 90.8 (88.7–92.6)
E23.0x ≥ 3 and/or E89.3x ≥ 1 777/973 79.9 (77.2–82.3) 85.3 (82.8–87.5)
E23.0x ≥ 5 and/or E89.3x ≥ 1 755/906 83.3 (80.7–85.7) 82.9 (80.3–85.3)
2. Algorithms for at least one, three or five records of E23.0x and/or at least one record of E89.3x and/or at least one record of HR
E23.0x ≥ 1 and/or E89.3x ≥ 1 or HR ≥ 1 859/1,173 73.2 (70.6–75.7) 94.3 (92.6–95.7)
E23.0x ≥ 3 and/or E89.3x ≥ 1 or HR ≥ 1 828/1,043 79.4 (76.8–81.8) 90.9 (88.8–92.7)
E23.0x ≥ 5 and/or E89.3x ≥ 1 or HR ≥ 1 817/989 82.6 (80.1–84.9) 89.7 (87.5–91.6)
Note: aCompleteness: proportion of confirmed hypopituitary patients detected during search of the DNPR for the specific ICD-10 code.
Abbreviations: ICD-10, International Classification of Diseases (10th edition); PPV, positive predictive value; CI, confidence interval; DNPR, Danish National Patient 
Registry; HR, hormone replacement.
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In general, the accuracy of clinical coding may relate to 
how closely a clinical condition reflects a relevant code, with 
the lowest accuracy relating to rare, ill-defined or complex 
conditions.12 Comparing Danish validation studies on more 
or less complex conditions,9,13–15 this may also apply to the 
coding in the DNPR. In this study, the accuracy of postpro-
cedural hypopituitarism (E89.3x) was distinctly superior to 
hypopituitarism (E23.0x). This difference possibly reflects the 
inbuilt specification of prior cranial surgery or irradiation in 
E89.3x, as these are procedures that per se increase the risk 
of hypopituitarism, and thus may the diagnostic code E89.3x 
reflect the clinical condition more accurately.
The accuracy of coding in the DNPR in the present study 
was also related to the year of incidence (before or after 
2000), with the lowest accuracy in the later period (Table 4). 
The more accurate coding before 2000 may be due to diagno-
sis of primarily severely affected patients at that time, making 
subsequent confirmation of hypopituitarism during medical 
record review easier. However, it may also reflect less optimal 
coding practice in the later period, with more patients being 
coded as hypopituitary without truly being hypopituitary.
Comparing men and women, a more accurate coding was 
observed in men. In one of our previous studies on GHD, 
where a similar approach as in the present study was used 
for identification of GHD patients, significantly more men 
than women were verified with GHD as well.8 Women have 
significantly more visits at their general practitioner than men 
(www.dst.dk), and we therefore speculate whether women 
with, e.g., pituitary adenomas are detected and referred to 
hospital by their general practitioner with smaller adenomas 
than men subsequently reducing the risk of postprocedural 
hypopituitarism. Further, postmenopausal women may 
receive a diagnosis of gonadotropin deficiency less likely 
than men may.
PPVs increased for the algorithms with increasing number 
of records of E23.0x (hypopituitarism). This complies with 
findings in similar studies, which, similar to hypopituita-
rism, require continued follow-up.9,15 Thus, it is possible 
that searches including repeated coding with specific ICD 
diagnoses will increase the accuracy of the data found in the 
DNPR for patients with other chronic conditions requiring 
continuing hospital follow-up as well.
Approximately 10% (9.2%, 84/911) of the confirmed 
hypopituitary patients had no records of E23.0x (hypopituita-
rism) or E89.3x (postprocedural hypopituitarism). Therefore, 
some underreporting of hypopituitarism is present, and it 
cannot be ruled out that it is even more prevalent than here. 
However, the prevalence of hypopituitarism was estimated to 
be 74.5 per 100,000. This estimate is ~50% higher than the 
only previously reported estimate of hypopituitarism of 45.5 
per 100,000 in a study from Spain,16 and therefore it seems 
likely that only very few diagnosed hypopituitary patients, 
if any, have been missed, when the candidate population was 
identified. It should, however, be stressed that the prevalence 
of 74.5 per 100,000 is a minimum estimate since some hypo-
pituitary individuals may remain undiagnosed. Further, some 
may have received a diagnosis from their general practitioner, 
thus were never recorded in the DNPR with an ICD-10 diag-
nosis of hypopituitarism or related pituitary disease. Never-
theless, we believe that this is rare. In general, an observed 
under- or overreporting of a certain disease could be due to 
discrepancy between diagnostic criteria used in the daily 
clinic and diagnostic criteria used in a study. In the present 
study, however, the diagnostic criteria of hypopituitarism are 
in accordance with the clinical guidelines of hypopituitarism 
from the Endocrine Society.17
Searching the candidate population for individuals with 
a registration of hormone replacement, the PPV was expect-
edly high (89.3%), but completeness was poor (65.1%). The 
data on hormone replacement therapy retrieved from the 
pharmacy at Aarhus University Hospital were the only data 
uniformly collected during the entire period 2000–2012, 
where the candidate population was identified. By contrast, 
data retrieved from endocrine and pediatric departments at 
the peripheral hospitals in the Central Denmark Region were 
of poor quality, since they had not been collected uniformly, 
and a considerable proportion of data had been destroyed. 
The poor quality was mirrored by the fact that only seven 
additional hormone replaced patients were identified at 
our search at the peripheral hospitals. In 2014, a uniform 
electronic registration of hormones administered directly 
to patients by hospital pharmacies in Central Denmark 
Region was established, and thus completeness is believed 
to increase for future populations of hypopituitary patients. 
However, some departments at the peripheral hospitals still 
retrieve hormones from the peripheral hospital pharmacies 
for administration to patients without an individual-level 
registration at the pharmacy. Part of the low completeness 
observed, searching the candidate population for patients 
receiving hormone replacement, could also be due to an 
incorrect prescription procedure of hormones by the treating 
physician, but we believe that this is rare, thus having only 
a minor influence on the estimate.
Hypopituitary patients constitute a very heterogeneous 
group of patients as the type and extent of hormonal loss 
differ among patients, and furthermore the etiology of 
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 hypopituitarism contributes to the heterogeneity. A larger 
proportion of the confirmed patients not identified by the 
algorithm (including at least five records of E23.0x and/or 
at least one record of E89.3x; 54.5%) had either idiopathic 
hypopituitarism or hypopituitarism due to adenomas or 
prolactinomas than confirmed patients that were identified 
by the algorithm (39.2%). An association between mortality 
and cause of hypopituitarism has been demonstrated, and 
mortality was, e.g., lower in hypopituitary patients due to 
adenomas than due to craniopharyngeomas or cancer.3,18 Con-
sidering this, the difference between algorithm-identified and 
algorithm-unidentified patients may indicate that high-risk 
patients are more likely to be correctly coded in the DNPR.
Some limitations must be considered when interpreting 
the results of this study. First, the study is based on findings 
from one Danish region only and as such, we cannot account 
for the remaining regions. An optimal study design would 
include evaluation of the algorithms on another study popula-
tion in another region. Due to the large number of additional 
medical records to be reviewed such a design was however 
considered unfeasible, and considering that Denmark is a 
welfare state with only small demographic variations between 
regions combined with the uniform public health system, we 
find it reasonable to consider results from one region repre-
sentative for the entire country. A second limitation is related 
to the verification process applied to the study population, as 
the reviewer was nonblinded to the ICD-10 diagnoses of the 
patients. However, we find it unlikely that this should have 
had any major influence on our study results.
In this study, including ~1.3 million inhabitants in Central 
Denmark Region during 2000–2012, the DNPR is found to 
be a valuable source to identify hypopituitary patients if an 
algorithm-based search is used. We recommend use of an 
algorithm including at least five records of hypopituitarism 
and/or at least one record of postprocedural hypopituitarism. 
Completeness can be improved by adding a criterion of at 
least one record of hormone replacement due to hypopitu-
itarism to the algorithm.
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